AU2022206461B2 - Anti-n3pglu amyloid beta antibodies and uses thereof - Google Patents

Anti-n3pglu amyloid beta antibodies and uses thereof

Info

Publication number
AU2022206461B2
AU2022206461B2 AU2022206461A AU2022206461A AU2022206461B2 AU 2022206461 B2 AU2022206461 B2 AU 2022206461B2 AU 2022206461 A AU2022206461 A AU 2022206461A AU 2022206461 A AU2022206461 A AU 2022206461A AU 2022206461 B2 AU2022206461 B2 AU 2022206461B2
Authority
AU
Australia
Prior art keywords
subject
antibody
n3pglu
weeks
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022206461A
Other languages
English (en)
Other versions
AU2022206461A1 (en
Inventor
Adam S. FLEISHER
Mark Mintun
John Randall II SIMS
JonDavid SPARKS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2022206461A1 publication Critical patent/AU2022206461A1/en
Application granted granted Critical
Publication of AU2022206461B2 publication Critical patent/AU2022206461B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022206461A 2021-01-11 2022-01-11 Anti-n3pglu amyloid beta antibodies and uses thereof Active AU2022206461B2 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163135932P 2021-01-11 2021-01-11
US63/135,932 2021-01-11
US202163155029P 2021-03-01 2021-03-01
US63/155,029 2021-03-01
US202163160380P 2021-03-12 2021-03-12
US63/160,380 2021-03-12
US202163192262P 2021-05-24 2021-05-24
US63/192,262 2021-05-24
US202163227054P 2021-07-29 2021-07-29
US63/227,054 2021-07-29
US202163277298P 2021-11-09 2021-11-09
US63/277,298 2021-11-09
US202163284248P 2021-11-30 2021-11-30
US63/284,248 2021-11-30
US202263296694P 2022-01-05 2022-01-05
US63/296,694 2022-01-05
PCT/US2022/011894 WO2022150735A1 (en) 2021-01-11 2022-01-11 Anti-n3pglu amyloid beta antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2022206461A1 AU2022206461A1 (en) 2023-06-29
AU2022206461B2 true AU2022206461B2 (en) 2026-02-05

Family

ID=80123357

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022206461A Active AU2022206461B2 (en) 2021-01-11 2022-01-11 Anti-n3pglu amyloid beta antibodies and uses thereof

Country Status (15)

Country Link
US (1) US20240010713A1 (https=)
EP (1) EP4274611A1 (https=)
JP (2) JP7676556B2 (https=)
KR (2) KR20260047659A (https=)
AU (1) AU2022206461B2 (https=)
CA (1) CA3204444A1 (https=)
CL (1) CL2023001992A1 (https=)
CO (1) CO2023009089A2 (https=)
EC (1) ECSP23051813A (https=)
IL (1) IL304072A (https=)
MX (1) MX2023008196A (https=)
PE (1) PE20231748A1 (https=)
TW (1) TWI843040B (https=)
WO (1) WO2022150735A1 (https=)
ZA (1) ZA202306180B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022307687A1 (en) * 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
WO2023039107A2 (en) 2021-09-09 2023-03-16 Alzpath, Inc. Phospho-tau antibodies and methods of use
CA3243602A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease
KR20250107906A (ko) * 2022-11-17 2025-07-14 일라이 릴리 앤드 캄파니 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
KR20250173598A (ko) * 2023-03-16 2025-12-10 알즈패스, 인크. 신경퇴행성 질환의 진단 및 치료 방법
WO2025231343A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for neurodegenerative diseases
WO2025240435A1 (en) * 2024-05-14 2025-11-20 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2018005282A1 (en) * 2016-07-01 2018-01-04 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
SI1720909T1 (sl) 2004-02-23 2012-01-31 Lilly Co Eli Anti-abeta protitelo
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
PL3042917T3 (pl) 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI789644B (zh) 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN107289872A (zh) 2017-06-28 2017-10-24 京东方科技集团股份有限公司 测高装置
KR102905634B1 (ko) 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2018005282A1 (en) * 2016-07-01 2018-01-04 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
TWI843040B (zh) 2024-05-21
AU2022206461A1 (en) 2023-06-29
ZA202306180B (en) 2025-02-26
PE20231748A1 (es) 2023-11-06
TW202243690A (zh) 2022-11-16
IL304072A (en) 2023-08-01
MX2023008196A (es) 2023-07-18
KR20260047659A (ko) 2026-04-08
CA3204444A1 (en) 2022-07-14
WO2022150735A1 (en) 2022-07-14
KR20230130695A (ko) 2023-09-12
EP4274611A1 (en) 2023-11-15
CO2023009089A2 (es) 2023-09-29
KR102942744B1 (ko) 2026-03-23
JP7676556B2 (ja) 2025-05-14
CL2023001992A1 (es) 2024-02-02
US20240010713A1 (en) 2024-01-11
JP2025131566A (ja) 2025-09-09
JP2024503025A (ja) 2024-01-24
ECSP23051813A (es) 2023-08-31

Similar Documents

Publication Publication Date Title
AU2022206461B2 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
AU2022232936B2 (en) Anti-amyloid beta antibodies and uses thereof
EP3464350A1 (en) Methods for treating alzheimer's disease
TW202317192A (zh) 用於阿茲海默氏症治療的生物標記物
US20250377367A1 (en) Methods of treatment using p-tau181 level
TW202430554A (zh) 使用ｔａｕ ＰＥＴ水平之治療方法
EA052116B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и варианты их применения
Pascual‐Lucas et al. Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double‐blind, placebo‐controlled phase 2 study
Krick et al. A Change of Mind: Targeting Amyloid-β with Better Safety Profile
CN116916957A (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
CN116981690A (zh) 抗-淀粉样蛋白β抗体及其用途
WO2026075947A1 (en) Dosing regimens for early alzheimer's disease
WO2026055601A1 (en) METHOD OF TREATING ALZHEIMER'S DISEASE USING ANTI-N3pGlu AMYLOID BETA ANTIBODIES
WO2022251048A1 (en) Anti-amyloid beta antibodies and uses thereof
KR20260038283A (ko) 항미생물 펩티드
NZ788486A (en) Methods for treating Alzheimer's disease